algeta asa
play

Algeta ASA - PowerPoint PPT Presentation

Algeta ASA Andrew Kay, President & CEO Jefferies 2010 Global Life


  1. Algeta ASA ����������������������������������������� ���������������� Andrew Kay, President & CEO Jefferies 2010 Global Life Sciences Conference 2010 V10

  2. Safe Harbor Statement THIS PRESENTATION AND ITS ENCLOSURES AND APPENDICES (HEREINAFTER JOINTLY REFERRED TO AS THE “PRESENTATION” HAS BEEN PREPARED BY ALGETA ASA (THE “COMPANY”) EXCLUSIVELY FOR INFORMATION PURPOSES. THIS PRESENTATION HAS NOT BEEN REVIEWED OR REGISTERED WITH ANY PUBLIC AUTHORITY OR STOCK EXCHANGE. RECIPIENTS OF THIS PRESENTATION MAY NOT REPRODUCE, REDISTRIBUTE OR PASS ON, IN WHOLE OR IN PART, THE PRESENTATION TO ANY OTHER PERSON.THE CONTENTS OF THIS PRESENTATION ARE NOT TO BE CONSTRUED AS LEGAL, BUSINESS, INVESTMENT OR TAX ADVICE. EACH RECIPIENT SHOULD CONSULT WITH ITS OWN LEGAL, BUSINESS, INVESTMENT AND TAX ADVISER AS TO LEGAL, BUSINESS, INVESTMENT AND TAX ADVICE.THERE MAY HAVE BEEN CHANGES IN MATTERS THAT AFFECT THE COMPANY SUBSEQUENT TO THE DATE OF THIS PRESENTATION. NEITHER THE ISSUE NOR DELIVERY OF THIS PRESENTATION SHALL UNDER ANY CIRCUMSTANCE CREATE ANY IMPLICATION THAT THE INFORMATION CONTAINED HEREIN IS CORRECT AS OF ANY TIME SUBSEQUENT TO THE DATE HEREOF OR THAT THE AFFAIRS OF THE COMPANY HAVE NOT SINCE CHANGED, AND THE COMPANY DOES NOT INTEND, AND DOES NOT ASSUME ANY OBLIGATION, TO UPDATE OR CORRECT ANY INFORMATION INCLUDED IN THIS PRESENTATION.THIS PRESENTATION INCLUDES AND IS BASED ON, AMONG OTHER THINGS, FORWARD6LOOKING INFORMATION AND STATEMENTS. SUCH FORWARD6LOOKING INFORMATION AND STATEMENTS ARE BASED ON THE CURRENT EXPECTATIONS, ESTIMATES AND PROJECTIONS OF THE COMPANY OR ASSUMPTIONS BASED ON INFORMATION AVAILABLE TO THE COMPANY. SUCH FORWARD6LOOKING INFORMATION AND STATEMENTS REFLECT CURRENT VIEWS WITH RESPECT TO FUTURE EVENTS AND ARE SUBJECT TO RISKS, UNCERTAINTIES AND ASSUMPTIONS. THE COMPANY CANNOT GIVE ANY ASSURANCE AS TO THE CORRECTNESS OF SUCH INFORMATION AND STATEMENTS. AN INVESTMENT IN THE COMPANY INVOLVES RISK, AND SEVERAL FACTORS COULD CAUSE THE ACTUAL RESULTS, PERFORMANCE OR ACHIEVEMENTS OF THE COMPANY TO BE MATERIALLY DIFFERENT FROM ANY FUTURE RESULTS, PERFORMANCE OR ACHIEVEMENTS THAT MAY BE EXPRESSED OR IMPLIED BY STATEMENTS AND INFORMATION IN THIS PRESENTATION, INCLUDING, AMONG OTHERS, RISKS OR UNCERTAINTIES ASSOCIATED WITH THE COMPANY’S BUSINESS, SEGMENTS, DEVELOPMENT, GROWTH MANAGEMENT, FINANCING, MARKET ACCEPTANCE AND RELATIONS WITH CUSTOMERS, AND, MORE GENERALLY, GENERAL ECONOMIC AND BUSINESS CONDITIONS, CHANGES IN DOMESTIC AND FOREIGN LAWS AND REGULATIONS, TAXES, CHANGES IN COMPETITION AND PRICING ENVIRONMENTS, FLUCTUATIONS IN CURRENCY EXCHANGE RATES AND INTEREST RATES AND OTHER FACTORS. SHOULD ONE OR MORE OF THESE RISKS OR UNCERTAINTIES MATERIALISE, OR SHOULD UNDERLYING ASSUMPTIONS PROVE INCORRECT, ACTUAL RESULTS MAY VARY MATERIALLY FROM THOSE DESCRIBED IN THIS DOCUMENT. THE COMPANY DOES NOT INTEND, AND DOES NOT ASSUME ANY OBLIGATION, TO UPDATE OR CORRECT THE INFORMATION INCLUDED IN THIS PRESENTATION. This Presentation does not constitute an offer or invitation for the sale or purchase of securities or assets in any jurisdiction, and neither this document nor anything contained herein shall form the basis of, or be relied upon in connection with, any contract or commitment whatsoever. The shares have not been registered under the Securities Act of 1933, as amended (the “Act"), or any applicable U.S. state securities laws, and may not be offered, sold or otherwise transferred, pledged or hypothecated unless (i) pursuant to registration under the act or (ii) in compliance with an exemption therefrom. 2

  3. History of Algeta ,--. • ����������� 6 Promise of Alpha6Pharmaceuticals 6 Unique alpha emitting proprietary technology 6 Strong IP position /%%. • ���������������������������� 6 USD 41m IPO • ����������������� /%%$ 6 ALSYMPCA pivotal global trial • ������������������ – USD 37m /%%- • ��!���"�#�$%%�������������������&�'�� • (��������������)������"�#�*+%%� /%,% 6 Cash USD 84m (end 1Q10) 3

  4. Algeta – A Focused Oncology Company • #������������������������������������������������������������� Potent and localized cancer cell killing activity – • �����������������!��������������������������������!�������������� An area of high medical need and significant commercial potential – Phase II data: Overall survival, QoL and highly tolerable side6effect profile – • ���������������������������������������������������'����������� – Major partnership; Phase III recruitment on schedule, trial expansion • ��!���"�#�$%%������������������������&�'����������������� 4

  5. Goal: A First Choice Treatment for Bone Metastases ����������� Phase I and II clinical trials in over 330 patients with bone metastases – Impressive Overall Survival in CRPC phase II (>40% increase p=0.017) – Enhanced Quality of Life – Highly tolerable side6effect profile – Ideal addition to cancer treatment regimes – Controls pain – Easy to use 6 out6patient procedure (���������������������������������������0 ����������������������������������������������� ������������������������������������� Sources: US market research commissioned from Decision Resources (May 2008) EU market research commissioned from Bridgehead (May 2008) 5

  6. Why Target Bone Metastases? • Bone metastases occur in up to 90% of certain late6stage cancers − E.g. prostate, breast, lung • For many patients there is no effective treatment • Bone metastases profoundly impair patient QoL and further reduce life expectancy "Bone metastases are associated with significant pain, neurological symptoms, pathological bone fractures, hypercalcaemia, and pancytopenia ultimately leading to death 12 Ref: Mundy GR. Metastasis to bone: Nat Rev Cancer. 2002;2:5846593 6

  7. Bone Metastases: High Incidence in Prostate Cancer &����(����������34�3 �������5�"�� *-67%%% �������� ���������������� :���'���������� 8��������� *.$/7%%%��������� ;+$67%%%���� ���������������< ���������������� #����� 8��������� */+97%%%� �������� Incidence in EU, top 5 Incidence in US Sources: prostate metastasis incidence data are company estimates, based on mortality data from SEER for US and Ferlay et al (Annals of Oncology. 2007) for EU. Incidence data for breast and lung cancers in EU are derived from ‘top 5’ incidence data contained in Datamonitor Stakeholder Opinion report published March 2008. Global Cancer Facts & Figures 2007, American Cancer Society 7

  8. Alpharadin: Targeting Multiple Bone Metastases Markets BONE METASTASES Prostate (CRPC) Alpharadin Breast (Endocrine refractory) ���� � ������ � • Alpharadin prescribed after bone metastases are diagnosed “It is estimated that more than 1.5 million cancer patients worldwide have bone metastases.” • Complimentary to therapy given to treat primary cancer ����������������������������������������������������� �� � !"����#��$�����%�&�� "�'(()"�*����+() ���,������*�������������-����� �����-������������-����-�����.���*���� 8

  9. Alpharadin: Highly Targeted to Bone Metastases Alpharadin is a new class alpha6pharmaceutical &���������� =���� ����� �����!���� ����� �������� ��������� 4������//? ���������� ���������� :���' ������� !��� =�����������!����������������� �������������>����������������� • Alpharadin (radium6223 in solution) acts as a calcium mimic – Naturally targets new bone growth in and around bone metastases • Alpha particles induce double6strand DNA breaks in adjacent tumor cells – Short penetration of alpha emitters (2610 cell diameters) means highly localized tumor cell killing & minimal damage to surrounding normal tissue • Alpharadin is cleared rapidly into small intestine 9

Recommend


More recommend